Key result
Dahuang-Shengjiang-Banxia Decoction targets diabetic kidney disease via 6 active ingredients and the VEGF/PI3K/AKT pathway.
Why the study?
The molecular mechanism of Dahuang-Shengjiang-Banxia Decoction in the treatment of diabetic kidney disease was not fully understood.
Answers are grounded in this paper and cite their sources.
Network pharmacology and molecular docking suggest that Dahuang-Shengjiang-Banxia Decoction may treat diabetic kidney disease via the VEGF/PI3K/AKT signaling pathway.
Background: Explore the molecular mechanism of Dahuang-Shengjiang-Banxia Decoction (DSBD) in the treatment of diabetic kidney disease (DKD), using network pharmacology and molecular docking technology. Method: The effective ingredients and targets of the DSBD were taken from the TCMSP database, while the disease targets were obtained via GeneCards, OMIM, DrugBank, TTD, and DisGeNET. Cytoscape 3.9.1 was used to create a drug-ingredient-target network diagram. STRING databases are also used to analyze the Protein-Protein Interaction (PPI) network of intersecting targets. The core targets was obtained by the intersection of the differential genes screened from the intersection target and GEO, and the core targets was enriched by Gene ontology (GO), Kyoto gene and genome (KEGG), and Gene Set Enrichment Analysis (GSEA). CIBERSORTx was used for immunoinfiltration analysis, and then the core targets was analyzed by Nephroseq V5 and KIT for clinical correlation analysis and single-cell sequencing. Lastly, AutoDock Vina was used for molecular docking of both the core targets and the top active elements. The top 6 active ingredients are 6-gingerol, baicalin, oleic acid, β-sitosterol, linolenic acid, and aloe emodin. The core targets has good docking activity with the active ingredient. Conclusion: is a key target in therapy, and that the VEGF/PI3K/AKT signaling pathway plays a key role in therapy.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2024) studied diabetic kidney disease (DKD). Dahuang-Shengjiang-Banxia Decoction (DSBD) was evaluated. Dahuang-Shengjiang-Banxia Decoction targets diabetic kidney disease via 6 key active ingredients, including 6-gingerol and baicalin, and the VEGF/PI3K/AKT signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: